Datasets:
prompt stringclasses 2
values | completion stringlengths 85 307 | enhanced_prompt stringlengths 948 2.01k | enhanced_completion stringlengths 210 1.37k | reasoning_trace stringlengths 1.85k 7.24k | context stringlengths 789 1.6k | original_context stringlengths 789 1.6k | persona_injection stringlengths 836 1k |
|---|---|---|---|---|---|---|---|
Summarize the main finding of this biomedical study in one sentence. | T cell proliferative capacity and persistence determine the therapeutic efficacy of chimeric antigen receptor (CAR) T cells. | ### Task
Summarize the main finding of the biomedical study provided below into exactly one sentence.
### Input Data
**Title:** Programmable CAR-engaging particles rewire human CAR T-cell signaling for sustainable ex vivo expansion.
**Abstract:** T cell proliferative capacity and persistence determine the therapeutic ... | Programmable DNA-scaffolded PLGA microparticles termed CAREp, which display CAR-targeting antigens and CD28-costimulatory antibodies, enable sustainable ex vivo expansion of human CAR-T cells without genetic rewiring by utilizing nanoscale ligand organization to synchronize acute signaling with durable proliferative an... | Okay, I need to summarize this biomedical study into exactly one sentence. Let me break down what's happening here.
The study is about CAREp — these are programmable DNA-scaffolded PLGA microparticles that display CAR-targeting antigens and CD28-costimulatory antibodies. The core problem they're addressing is that CAR... | Title: Programmable CAR-engaging particles rewire human CAR T-cell signaling for sustainable ex vivo expansion. | Abstract: T cell proliferative capacity and persistence determine the therapeutic efficacy of chimeric antigen receptor (CAR) T cells. However, strategies to externally enhance CAR-T cell expansion without ... | Title: Programmable CAR-engaging particles rewire human CAR T-cell signaling for sustainable ex vivo expansion. | Abstract: T cell proliferative capacity and persistence determine the therapeutic efficacy of chimeric antigen receptor (CAR) T cells. However, strategies to externally enhance CAR-T cell expansion without ... | # Constraints
The question you must answer is from a science domain. You are a senior immunologist and CAR-T cell therapy researcher with 15 years of experience in synthetic biology and translational oncology. Based in a leading Boston biotech hub, you specialize in T-cell signaling pathways and ex vivo expansion techn... |
Summarize the main finding of this biomedical study in one sentence. | Claudin 18.2 (CLDN18.2) is a promising therapeutic target in gastric/esophagogastric junction adenocarcinoma (GC/EGJC), but its dynamic expression during systemic therapy is unclear. | # Task
Summarize the main finding of the biomedical study provided below into exactly one sentence.
# Study Content
**Title:** Dynamic changes of claudin 18.2 expression after systemic therapy in gastric and esophagogastric junction cancer.
**Abstract:** Claudin 18.2 (CLDN18.2) is a promising therapeutic target in ga... | Systemic therapy for gastric and esophagogastric junction adenocarcinoma induces highly dynamic changes in Claudin 18.2 expression, with over 84% of patients demonstrating altered expression levels and significant bidirectional conversion between positive and negative status regardless of the treatment regimen, resulti... | Let me carefully read through this study abstract and figure out what the main finding is.
Okay, so the study is looking at Claudin 18.2 (CLDN18.2) expression in gastric and esophagogastric junction adenocarcinoma — specifically how it changes dynamically during systemic therapy. They evaluated paired tumor samples fr... | Title: Dynamic changes of claudin 18.2 expression after systemic therapy in gastric and esophagogastric junction cancer. | Abstract: Claudin 18.2 (CLDN18.2) is a promising therapeutic target in gastric/esophagogastric junction adenocarcinoma (GC/EGJC), but its dynamic expression during systemic therapy is unclear. CLDN... | Title: Dynamic changes of claudin 18.2 expression after systemic therapy in gastric and esophagogastric junction cancer. | Abstract: Claudin 18.2 (CLDN18.2) is a promising therapeutic target in gastric/esophagogastric junction adenocarcinoma (GC/EGJC), but its dynamic expression during systemic therapy is unclear. CLDN... | # Constraints
The question you must answer is from a medical domain. You are a senior oncologist and translational researcher specializing in gastric cancer biomarkers. With 15 years of clinical experience and a focus on immunohistochemistry, you expertly interpret dynamic protein expression changes to guide systemic t... |
List the MeSH terms that index this study. | Humans | Carcinoma, Non-Small-Cell Lung | Female | Antibodies, Monoclonal, Humanized | Antibodies, Monoclonal | Male | Lung Neoplasms | Aged | Middle Aged | Chemoradiotherapy | Neoplasm Staging | Antineoplastic Combined Chemotherapy Protocols | Adult | Progression-Free Survival | Consolidation Chemotherapy | Extract and list the Medical Subject Headings (MeSH) terms that index the provided study.
**Input Data:**
Title: Canakinumab with chemoradiation and durvalumab consolidation in unresectable stage III non-small cell lung cancer: the phase I/II CHORUS trial. | Abstract: CHORUS (NCT04905316) was an open-label, non-random... | Based on the provided title and abstract, the following Medical Subject Headings (MeSH) terms are appropriate for indexing this study:
* Carcinoma, Non-Small-Cell Lung
* Lung Neoplasms
* Canakinumab
* Durvalumab
* Antibodies, Monoclonal, Humanized
* Immune Checkpoint Inhibitors
* Chemoradiotherapy
* Combined Modality ... | The user wants me to extract MeSH terms from a study. Let me break down what's in this abstract.
The study is the CHORUS trial - a phase I/II trial testing canakinumab (anti-IL-1β monoclonal antibody) with chemoradiation and durvalumab (anti-PD-L1) consolidation in unresectable stage III NSCLC.
Let me work through th... | Title: Canakinumab with chemoradiation and durvalumab consolidation in unresectable stage III non-small cell lung cancer: the phase I/II CHORUS trial. | Abstract: CHORUS (NCT04905316) was an open-label, non-randomized, single-arm phase I/II trial of the anti-IL-1beta monoclonal antibody canakinumab given with concurren... | Title: Canakinumab with chemoradiation and durvalumab consolidation in unresectable stage III non-small cell lung cancer: the phase I/II CHORUS trial. | Abstract: CHORUS (NCT04905316) was an open-label, non-randomized, single-arm phase I/II trial of the anti-IL-1beta monoclonal antibody canakinumab given with concurren... | # Constraints
The question you must answer is from a medical domain. You are a senior medical librarian and oncology research specialist with 15 years of experience in clinical trial indexing. You possess deep expertise in MeSH terminology, non-small cell lung cancer treatments, and immunotherapy protocols. Your precis... |
Summarize the main finding of this biomedical study in one sentence. | Currently, no immunotherapy is approved for T cell acute lymphoblastic leukemia (T‑ALL). | # Task: Biomedical Study Summary
Generate a single-sentence summary of the main finding from the study provided below.
## Constraints
- **Length**: Exactly one sentence.
- **Focus**: Capture the primary conclusion regarding the efficacy and safety of the proposed therapy.
- **Tone**: Professional and scientific.
## ... | This study establishes CD28 as a viable target for CAR T-cell therapy in T-lineage malignancies, demonstrating that CRISPR-engineered anti-CD28 CAR T cells achieve anti-tumor efficacy comparable to anti-CD7 CAR T cells while offering a superior safety profile characterized by markedly reduced lymphodepletion and the pr... | Okay, I need to write a single-sentence summary of this study. Let me break down what's happening here.
The study is about T-cell malignancies — specifically T-ALL and nodal T-follicular helper cell lymphomas. The problem is that current CD7-directed CAR T cells, while effective initially, cause severe T cell aplasia ... | Title: Targeting CD28 on T lineage malignancies with chimeric antigen receptor T cells. | Abstract: Currently, no immunotherapy is approved for T cell acute lymphoblastic leukemia (T‑ALL). High initial response rates to CD7‑directed chimeric antigen receptor (CAR) T cells are limited by profound T cell aplasia and CD7‑... | Title: Targeting CD28 on T lineage malignancies with chimeric antigen receptor T cells. | Abstract: Currently, no immunotherapy is approved for T cell acute lymphoblastic leukemia (T‑ALL). High initial response rates to CD7‑directed chimeric antigen receptor (CAR) T cells are limited by profound T cell aplasia and CD7‑... | # Constraints
The question you must answer is from a science domain. You are a senior translational immunologist and hematologist-oncologist specializing in CAR T-cell therapies for T-lineage malignancies. With over 15 years of experience in clinical trials and molecular engineering, you possess deep expertise in CD28 ... |
Summarize the main finding of this biomedical study in one sentence. | Hyperacute graft-versus-host disease (HA-GVHD) is a fulminant form of acute GVHD that develops early after allogeneic hematopoietic cell transplantation, before neutrophil engraftment ensues, and is associated with increased risk of non-relapse mortality. | You are an expert biomedical researcher. Summarize the main finding of the study provided below into a single, concise sentence.
### Definitions
- **HA-GVHD**: Hyperacute Graft-Versus-Host Disease, a fulminant form of acute GVHD occurring before neutrophil engraftment.
- **HLA**: Human Leukocyte Antigen.
### Input Te... | Hyperacute graft-versus-host disease is a fulminant, high-mortality complication occurring before neutrophil engraftment that is primarily managed with high-dose systemic corticosteroids, with ruxolitinib emerging as a potential therapy for refractory cases requiring further investigation. | Okay, let me carefully read through this prompt. I need to summarize the main finding of a study about HA-GVHD into a single, concise sentence.
Let me break down what the abstract is telling me:
1. HA-GVHD is a fulminant form of acute GVHD that occurs early after allogeneic HCT, before neutrophil engraftment
2. It's ... | Title: Hyperacute Graft-Versus-Host Disease. | Abstract: Hyperacute graft-versus-host disease (HA-GVHD) is a fulminant form of acute GVHD that develops early after allogeneic hematopoietic cell transplantation, before neutrophil engraftment ensues, and is associated with increased risk of non-relapse mortality. While i... | Title: Hyperacute Graft-Versus-Host Disease. | Abstract: Hyperacute graft-versus-host disease (HA-GVHD) is a fulminant form of acute GVHD that develops early after allogeneic hematopoietic cell transplantation, before neutrophil engraftment ensues, and is associated with increased risk of non-relapse mortality. While i... | # Constraints
The question you must answer is from a medical domain. You are a senior hematologist-oncologist specializing in allogeneic stem cell transplantation, with over 15 years of clinical and research experience in graft-versus-host disease. Based at a leading academic medical center, you routinely manage hypera... |
List the MeSH terms that index this study. | Humans | T-Lymphocytes, Regulatory | Histones | Colorectal Neoplasms | Glycerol | Animals | Tumor Microenvironment | Forkhead Transcription Factors | Liver Neoplasms | Mice | Feedback, Physiological | Identify and list the Medical Subject Headings (MeSH) terms that index the study described below. MeSH terms are a controlled vocabulary thesaurus used for indexing articles in PubMed.
Study Details:
Title: Histone H4K5 lactylation-driven feedback loop modulates glycerol-linked immunosuppressive activity of tumor-asso... | Based on the provided study title and abstract, the following Medical Subject Headings (MeSH) terms are appropriate for indexing:
**Primary MeSH Terms:**
* **Colorectal Neoplasms** (The primary cancer type studied)
* **Neoplasm Metastasis** (Focus on the spread to the liver)
* **Liver Neoplasms, Secondary** (The... | Alright, I need to identify MeSH terms for this study. Let me carefully read through the title and abstract.
Title: "Histone H4K5 lactylation-driven feedback loop modulates glycerol-linked immunosuppressive activity of tumor-associated T regulatory cells."
Key concepts I'm picking up here:
- Histone H4K5 lactylation ... | Title: Histone H4K5 lactylation-driven feedback loop modulates glycerol-linked immunosuppressive activity of tumor-associated T regulatory cells. | Abstract: Tumor metastasis is the leading cause of death for more than 90% of cancer patients, with colorectal cancer (CRC) mainly spreading to the liver. The colon and liv... | Title: Histone H4K5 lactylation-driven feedback loop modulates glycerol-linked immunosuppressive activity of tumor-associated T regulatory cells. | Abstract: Tumor metastasis is the leading cause of death for more than 90% of cancer patients, with colorectal cancer (CRC) mainly spreading to the liver. The colon and liv... | # Constraints
The question you must answer is from a science domain. You are a senior computational biologist and oncology researcher specializing in tumor immunology and epigenetics. With a PhD and over 15 years of experience analyzing single-cell data and spatial transcriptomics, you possess deep expertise in MeSH in... |
Summarize the main finding of this biomedical study in one sentence. | Tumor metastasis is the leading cause of death for more than 90% of cancer patients, with colorectal cancer (CRC) mainly spreading to the liver. | ### Task
Summarize the main finding of the provided biomedical study in exactly one sentence.
### Input Data
**Title:** Histone H4K5 lactylation-driven feedback loop modulates glycerol-linked immunosuppressive activity of tumor-associated T regulatory cells.
**Abstract:** Tumor metastasis is the leading cause of death... | This study identifies a glycerol-derived lactate-driven H4K5 histone lactylation feedback loop that upregulates FOXP3 and GK expression in CD177+GK+ regulatory T cells, amplifying their immunosuppressive activity to drive tumor immune evasion in colorectal cancer liver metastases, with therapeutic blockade of this meta... | Let me break down what this study is really about. The title mentions H4K5 lactylation, a feedback loop, glycerol, and Treg immunosuppressive activity — so the core is clearly metabolic-epigenetic regulation of Tregs in cancer.
Reading through the abstract, the key discovery chain is: glycerol-derived lactate drives H... | Title: Histone H4K5 lactylation-driven feedback loop modulates glycerol-linked immunosuppressive activity of tumor-associated T regulatory cells. | Abstract: Tumor metastasis is the leading cause of death for more than 90% of cancer patients, with colorectal cancer (CRC) mainly spreading to the liver. The colon and liv... | Title: Histone H4K5 lactylation-driven feedback loop modulates glycerol-linked immunosuppressive activity of tumor-associated T regulatory cells. | Abstract: Tumor metastasis is the leading cause of death for more than 90% of cancer patients, with colorectal cancer (CRC) mainly spreading to the liver. The colon and liv... | # Constraints
The question you must answer is from a science domain. You are a senior cancer immunologist and principal investigator specializing in tumor metabolism and epigenetic regulation. With over 15 years of experience analyzing single-cell data and spatial transcriptomics, you possess deep expertise in how meta... |
Summarize the main finding of this biomedical study in one sentence. | Acquired resistance to gemcitabine (GEM) remains a major barrier to effective treatment of pancreatic ductal adenocarcinoma (PDAC). | ### Task
Summarize the main finding of the provided biomedical study in exactly one sentence.
### Input Data
**Title:** Lactate-H3K18la-RPL11 Axis Drives Gemcitabine Resistance in Pancreatic Cancer by Integrating Protein Synthesis and DNA Damage Repair.
**Abstract:** Acquired resistance to gemcitabine (GEM) remains a ... | This study identifies a lactate-H3K18la-RPL11 axis that drives gemcitabine resistance in pancreatic ductal adenocarcinoma by epigenetically upregulating RPL11 to concurrently enhance global protein synthesis via EEF1A1 stabilization and DNA damage repair through PARP14 coactivation. | Okay, I need to summarize this biomedical study in exactly one sentence. Let me break down what's happening here.
The study is about gemcitabine resistance in pancreatic cancer (PDAC). The core finding seems to be this "lactate-H3K18la-RPL11 axis" — so gemcitabine causes lactate accumulation, which induces histone H3K... | Title: Lactate-H3K18la-RPL11 Axis Drives Gemcitabine Resistance in Pancreatic Cancer by Integrating Protein Synthesis and DNA Damage Repair. | Abstract: Acquired resistance to gemcitabine (GEM) remains a major barrier to effective treatment of pancreatic ductal adenocarcinoma (PDAC). Here we identify histone H3K18 lact... | Title: Lactate-H3K18la-RPL11 Axis Drives Gemcitabine Resistance in Pancreatic Cancer by Integrating Protein Synthesis and DNA Damage Repair. | Abstract: Acquired resistance to gemcitabine (GEM) remains a major barrier to effective treatment of pancreatic ductal adenocarcinoma (PDAC). Here we identify histone H3K18 lact... | # Constraints
The question you must answer is from a science domain. You are a senior oncology researcher and molecular biologist specializing in pancreatic cancer epigenetics. With a PhD and 15 years of lab experience, you expertly interpret complex metabolic pathways and histone modifications. Your precise analysis b... |
List the MeSH terms that index this study. | Humans | Signal Transduction | Receptors, Chimeric Antigen | Cell Proliferation | CD8-Positive T-Lymphocytes | Immunotherapy, Adoptive | CD28 Antigens | Mitochondria | Polylactic Acid-Polyglycolic Acid Copolymer | Lymphocyte Activation | ErbB Receptors | Identify and list the Medical Subject Headings (MeSH) terms that appropriately index the following scientific study.
<study_content>
Title: Programmable CAR-engaging particles rewire human CAR T-cell signaling for sustainable ex vivo expansion. | Abstract: T cell proliferative capacity and persistence determine the th... | Based on the provided study, the following Medical Subject Headings (MeSH) terms appropriately index the scientific content:
* Humans
* Receptors, Chimeric Antigen
* T-Lymphocytes
* CD8-Positive T-Lymphocytes
* Lymphocyte Activation
* Immunotherapy, Adoptive
* Cell Proliferation
* Cell Survival
* Ex Vivo Techniques
* ... | Let me analyze this study systematically to identify the appropriate MeSH terms.
The study is about engineering programmable particles (CAREp) to enhance CAR-T cell expansion ex vivo. Let me break down the key components:
**Subject/Population:**
- Human CAR-T cells (CD8+ specifically) → "Humans", "T-Lymphocytes", "CD... | Title: Programmable CAR-engaging particles rewire human CAR T-cell signaling for sustainable ex vivo expansion. | Abstract: T cell proliferative capacity and persistence determine the therapeutic efficacy of chimeric antigen receptor (CAR) T cells. However, strategies to externally enhance CAR-T cell expansion without ... | Title: Programmable CAR-engaging particles rewire human CAR T-cell signaling for sustainable ex vivo expansion. | Abstract: T cell proliferative capacity and persistence determine the therapeutic efficacy of chimeric antigen receptor (CAR) T cells. However, strategies to externally enhance CAR-T cell expansion without ... | # Constraints
The question you must answer is from a science domain. You are a senior biomedical librarian and immunology researcher specializing in CAR-T cell therapies. With a PhD in Molecular Biology and 15 years of experience indexing oncology studies, you possess encyclopedic knowledge of MeSH terminologies and T-... |
Summarize the main finding of this biomedical study in one sentence. | Outcomes for patients with resectable head and neck squamous cell carcinoma (HNSCC) remain suboptimal despite multimodal therapy, with high rates of recurrence and patients suffering from toxicity of treatments. | # Task: Biomedical Study Summary
Generate a single-sentence summary of the main finding from the study provided below.
## Constraints
- **Length**: Exactly one sentence.
- **Focus**: Capture the primary conclusion regarding therapeutic outcomes.
- **Tone**: Professional and scientific.
## Input Data
**Title**: Perio... | Recent phase III trials establish that adjuvant nivolumab and perioperative pembrolizumab significantly improve survival outcomes in resectable head and neck squamous cell carcinoma—disease-free survival with adjuvant nivolumab and event-free survival with perioperative pembrolizumab—supporting a paradigm shift toward ... | Alright, I need to write a single-sentence summary of the main finding from this study about perioperative immunotherapy in head and neck squamous cell carcinoma (HNSCC). Let me break down what's in this abstract.
The abstract is talking about several key points:
1. Current outcomes for resectable HNSCC are suboptimal... | Title: Perioperative immunotherapy in head and neck squamous cell carcinoma. | Abstract: Outcomes for patients with resectable head and neck squamous cell carcinoma (HNSCC) remain suboptimal despite multimodal therapy, with high rates of recurrence and patients suffering from toxicity of treatments. Immune checkpoint i... | Title: Perioperative immunotherapy in head and neck squamous cell carcinoma. | Abstract: Outcomes for patients with resectable head and neck squamous cell carcinoma (HNSCC) remain suboptimal despite multimodal therapy, with high rates of recurrence and patients suffering from toxicity of treatments. Immune checkpoint i... | # Constraints
The question you must answer is from a medical domain. You are a senior oncologist and clinical researcher specializing in head and neck cancers, currently leading perioperative immunotherapy trials at a major academic medical center. With over 15 years of experience, you possess deep expertise in interpr... |
Summarize the main finding of this biomedical study in one sentence. | Hepatocellular carcinoma (HCC) refractory to locoregional therapies remains a major clinical challenge. | # Task: Summarize Biomedical Study Finding
## Instructions
Analyze the provided biomedical study text below and generate a **single-sentence summary** of its main finding.
### Constraints
- **Length**: Exactly one sentence.
- **Focus**: Highlight the primary efficacy or safety outcome.
- **Tone**: Professional and sc... | In a phase IIa trial of patients with locally advanced hepatocellular carcinoma refractory to standard care, combining locoregional high-dose autologous natural killer cell therapy with hepatic arterial infusion chemotherapy achieved an independent review committee-assessed objective response rate of 68.75% and a disea... | Let me analyze this biomedical study text carefully. The title tells me this is a Phase IIa trial combining autologous NK cell therapy with HAIC for locally advanced HCC. The abstract describes the study design — patients refractory to standard care, the treatment protocol involving HAIC cycles followed by hepatic arte... | Title: Phase IIa Trial of Locoregional High-Dose Autologous Natural Killer Cell Therapy Combined with Hepatic Arterial Infusion Chemotherapy for Locally Advanced Hepatocellular Carcinoma. | Abstract: Hepatocellular carcinoma (HCC) refractory to locoregional therapies remains a major clinical challenge. This study evalu... | Title: Phase IIa Trial of Locoregional High-Dose Autologous Natural Killer Cell Therapy Combined with Hepatic Arterial Infusion Chemotherapy for Locally Advanced Hepatocellular Carcinoma. | Abstract: Hepatocellular carcinoma (HCC) refractory to locoregional therapies remains a major clinical challenge. This study evalu... | # Constraints
The question you must answer is from a medical domain. You are a senior oncologist and clinical researcher specializing in hepatocellular carcinoma and immunotherapy. With over 15 years of experience interpreting phase II trials, you possess deep expertise in NK cell therapies and hepatic arterial infusio... |
Summarize the main finding of this biomedical study in one sentence. | CHORUS (NCT04905316) was an open-label, non-randomized, single-arm phase I/II trial of the anti-IL-1beta monoclonal antibody canakinumab given with concurrent chemoradiotherapy and continued with anti-PD-L1 durvalumab consolidation in unresectable stage III non-small cell lung cancer. | ### Task
Summarize the main finding of the provided biomedical study abstract into a single, concise sentence.
### Input Data
**Title:** Canakinumab with chemoradiation and durvalumab consolidation in unresectable stage III non-small cell lung cancer: the phase I/II CHORUS trial.
**Abstract:** CHORUS (NCT04905316) was... | The phase I/II CHORUS trial met its primary endpoint, demonstrating that canakinumab combined with concurrent chemoradiation and durvalumab consolidation achieved a 24-month progression-free survival rate of 67% in unresectable stage III non-small cell lung cancer, exceeding the 46% historical benchmark. | Let me break down this abstract. The key elements I need to capture:
1. **Study design**: Phase I/II CHORUS trial, single-arm
2. **Intervention**: Canakinumab (anti-IL-1β) + chemoradiation + durvalumab consolidation
3. **Population**: Unresectable stage III NSCLC
4. **Primary endpoint**: 24-month PFS from radiotherapy... | Title: Canakinumab with chemoradiation and durvalumab consolidation in unresectable stage III non-small cell lung cancer: the phase I/II CHORUS trial. | Abstract: CHORUS (NCT04905316) was an open-label, non-randomized, single-arm phase I/II trial of the anti-IL-1beta monoclonal antibody canakinumab given with concurren... | Title: Canakinumab with chemoradiation and durvalumab consolidation in unresectable stage III non-small cell lung cancer: the phase I/II CHORUS trial. | Abstract: CHORUS (NCT04905316) was an open-label, non-randomized, single-arm phase I/II trial of the anti-IL-1beta monoclonal antibody canakinumab given with concurren... | # Constraints
The question you must answer is from a medical domain. You are a senior oncologist and clinical trial investigator specializing in thoracic malignancies. With 20 years of experience in immunotherapy and chemoradiation, you possess deep expertise in interpreting phase I/II trial data. Your analytical preci... |
Summarize the main finding of this biomedical study in one sentence. | Cellular immunotherapies have shown great promise in the treatment of various diseases. | # Task: Summarize Biomedical Study Finding
**Objective**: Analyze the provided biomedical study text and summarize its main finding in exactly one sentence.
**Instructions**:
1. Read the study title and abstract provided below.
2. Identify the primary outcome regarding safety, tissue distribution, or antiviral activi... | In SIV-infected rhesus macaques, the autologous infusion of CER-1236 T cells was well tolerated, with neither animal exhibiting clinical illness or physiological changes beyond those typically associated with SIV infection. | The prompt asks me to summarize a biomedical study's main finding in exactly one sentence. Let me carefully read through the title and abstract.
The title tells me this is about safety of autologous CER T cell infusion in nonhuman primates. The abstract gives me the background: CER-engineered T cells use TIM-4 domains... | Title: Safety of Autologous Infusion of CER T Cells in Nonhuman Primates. | Abstract: Cellular immunotherapies have shown great promise in the treatment of various diseases. Chimeric engulfment receptor (CER)-engineered T cells were developed to utilize the extracellular T-cell immunoglobulin and mucin domain-containin... | Title: Safety of Autologous Infusion of CER T Cells in Nonhuman Primates. | Abstract: Cellular immunotherapies have shown great promise in the treatment of various diseases. Chimeric engulfment receptor (CER)-engineered T cells were developed to utilize the extracellular T-cell immunoglobulin and mucin domain-containin... | # Constraints
The question you must answer is from a science domain. You are a senior translational immunologist and virologist specializing in cellular therapies for infectious diseases. With over 15 years of experience designing preclinical nonhuman primate studies, you expertly interpret complex abstracts on CAR/CER... |
Summarize the main finding of this biomedical study in one sentence. | Anaplastic thyroid carcinoma (ATC) is a lethal malignancy with a dismal prognosis and limited therapeutic options. | # Task: Biomedical Study Summary
Generate a concise, one-sentence summary of the main finding from the provided biomedical study text below.
## Constraints
- **Length**: Exactly one sentence.
- **Focus**: Capture the primary therapeutic mechanism and outcome.
- **Accuracy**: Base the summary strictly on the provided ... | Zingiberen newsaponin suppresses anaplastic thyroid carcinoma and enhances antitumor immunity by inducing autophagy-dependent, GSDME-mediated pyroptosis, thereby sensitizing the malignancy to anti-PD-1 therapy. | Okay, let me parse this prompt. I need to generate a one-sentence summary of a biomedical study about Zingiberen newsaponin (ZN) in anaplastic thyroid carcinoma (ATC). The summary must capture the primary therapeutic mechanism and outcome, based strictly on the provided text.
Let me break down the key information from... | Title: Zingiberen Newsaponin Enhances Antitumor Immunity in Anaplastic Thyroid Carcinoma Via Induction of Autophagy-Dependent Pyroptosis. | Abstract: Anaplastic thyroid carcinoma (ATC) is a lethal malignancy with a dismal prognosis and limited therapeutic options. Although immunotherapy has revolutionized the oncologic... | Title: Zingiberen Newsaponin Enhances Antitumor Immunity in Anaplastic Thyroid Carcinoma Via Induction of Autophagy-Dependent Pyroptosis. | Abstract: Anaplastic thyroid carcinoma (ATC) is a lethal malignancy with a dismal prognosis and limited therapeutic options. Although immunotherapy has revolutionized the oncologic... | # Constraints
The question you must answer is from a science domain. You are a senior oncology researcher and molecular biologist specializing in thyroid carcinoma and immunotherapy. With a PhD and 15 years of experience in translational medicine, you expertly interpret complex mechanisms like autophagy-dependent pyrop... |
List the MeSH terms that index this study. | Humans | CD28 Antigens | Receptors, Chimeric Antigen | Animals | Immunotherapy, Adoptive | Mice | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Adolescent | Child | Female | Mice, Inbred NOD | Male | CRISPR-Cas Systems | Analyze the provided biomedical study excerpt and list the Medical Subject Headings (MeSH) terms that best index this research.
**Study Excerpt:**
Title: Targeting CD28 on T lineage malignancies with chimeric antigen receptor T cells. | Abstract: Currently, no immunotherapy is approved for T cell acute lymphoblastic l... | Based on the provided study excerpt, the following Medical Subject Headings (MeSH) terms best index this research:
**Disease Targets**
* **Precursor T-Cell Lymphoblastic Leukemia-Lymphoma** (Covers T-ALL)
* **Lymphoma, T-Cell** (Covers nodal T-follicular helper cell lymphomas)
**Therapeutic Agents & Targets**
* **Rec... | Let me break down this study excerpt. The title mentions targeting CD28 on T lineage malignancies using CAR T cells. The abstract discusses T-ALL, nodal T-follicular helper cell lymphomas, CD28 as a target, CRISPR/Cas9 knockout, and anti-CD28 CAR T cells.
Let me work through the MeSH terms systematically.
**Disease e... | Title: Targeting CD28 on T lineage malignancies with chimeric antigen receptor T cells. | Abstract: Currently, no immunotherapy is approved for T cell acute lymphoblastic leukemia (T‑ALL). High initial response rates to CD7‑directed chimeric antigen receptor (CAR) T cells are limited by profound T cell aplasia and CD7‑... | Title: Targeting CD28 on T lineage malignancies with chimeric antigen receptor T cells. | Abstract: Currently, no immunotherapy is approved for T cell acute lymphoblastic leukemia (T‑ALL). High initial response rates to CD7‑directed chimeric antigen receptor (CAR) T cells are limited by profound T cell aplasia and CD7‑... | # Constraints
The question you must answer is from a science domain. You are a senior biomedical librarian and immunology researcher specializing in hematologic malignancies and CAR-T cell therapy. With a PhD in Molecular Biology and 15 years of experience indexing oncology studies for PubMed, you possess encyclopedic ... |
Summarize the main finding of this biomedical study in one sentence. | The distal small intestine has a vital role in host physiology through its regulation of nutrient and fluid homeostasis. | Analyze the provided biomedical study text and summarize its main finding in exactly one sentence.
### Input Text
**Title:** Diverse infections transcriptionally reprogram the intestinal epithelium and epithelial-immune cell interactions.
**Abstract:** The distal small intestine has a vital role in host physiology thr... | This study introduces GutPath, a comprehensive single-cell atlas of the ileum across diverse infections, revealing that pathogens transcriptionally reprogram the intestinal epithelium and epithelial-immune interactions while identifying a novel enterocyte state linked to Yersinia pseudotuberculosis pathology. | Okay, I need to analyze this biomedical study abstract and distill it into exactly one sentence that captures the primary finding or contribution. Let me break down what's in this abstract.
The title already tells me a lot: diverse infections transcriptionally reprogram the intestinal epithelium and epithelial-immune ... | Title: Diverse infections transcriptionally reprogram the intestinal epithelium and epithelial-immune cell interactions. | Abstract: The distal small intestine has a vital role in host physiology through its regulation of nutrient and fluid homeostasis. Despite being affected in Crohn's disease and serving as a major t... | Title: Diverse infections transcriptionally reprogram the intestinal epithelium and epithelial-immune cell interactions. | Abstract: The distal small intestine has a vital role in host physiology through its regulation of nutrient and fluid homeostasis. Despite being affected in Crohn's disease and serving as a major t... | # Constraints
The question you must answer is from a science domain. You are a senior computational immunologist and principal investigator specializing in single-cell genomics of the gut. With over 15 years of experience analyzing host-pathogen interactions, you possess deep expertise in transcriptional reprogramming ... |
Summarize the main finding of this biomedical study in one sentence. | Adoptive cellular therapies (ACT) have reshaped the treatment landscape of hematologic malignancies and are increasingly being explored in solid tumors. | ### Task
Summarize the principal finding of the provided biomedical study abstract into a single, concise sentence.
### Input Data
**Title:** Updates in CAR-T and TCR-T therapy for solid tumors from the 2026 ASCO Annual Meeting.
**Abstract:** Adoptive cellular therapies (ACT) have reshaped the treatment landscape of h... | This correspondence reviews the principal early-phase clinical trials for CAR-T and TCR-T therapies in solid tumors presented at the 2026 ASCO Annual Meeting, while noting that their application continues to be limited by antigen heterogeneity, immunosuppressive tumor microenvironments, manufacturing complexity, and sa... | Alright, let me read through this abstract carefully. The title tells me this is about updates in CAR-T and TCR-T therapy for solid tumors from the 2026 ASCO Annual Meeting. So the core subject is already clear — it's a summary of what was presented at ASCO 2026 regarding these adoptive cellular therapies in solid tumo... | Title: Updates in CAR-T and TCR-T therapy for solid tumors from the 2026 ASCO Annual Meeting. | Abstract: Adoptive cellular therapies (ACT) have reshaped the treatment landscape of hematologic malignancies and are increasingly being explored in solid tumors. Key approaches include chimeric antigen receptor T-cell (CAR-... | Title: Updates in CAR-T and TCR-T therapy for solid tumors from the 2026 ASCO Annual Meeting. | Abstract: Adoptive cellular therapies (ACT) have reshaped the treatment landscape of hematologic malignancies and are increasingly being explored in solid tumors. Key approaches include chimeric antigen receptor T-cell (CAR-... | # Constraints
The question you must answer is from a medical domain. You are a senior oncologist and translational researcher specializing in adoptive cellular therapies, currently based at a leading NCI-designated cancer center. With over 15 years of experience in CAR-T and TCR-T clinical trials, you regularly attend ... |
Summarize the main finding of this biomedical study in one sentence. | Late-stage non-small cell lung cancer (NSCLC) is rarely curable1, underscoring a need to intervene earlier in the disease process. | # Task: Summarize Biomedical Study Finding
## Instructions
Analyze the provided biomedical study text below and summarize its **main finding** in exactly **one sentence**.
## Constraints
- **Length**: Strictly one sentence.
- **Focus**: Identify the primary discovery regarding the relationship between specific T cell... | The study identifies a clonally coordinated axis of BATF-expressing effector regulatory CD4+ T cells (eTregs) that accumulates in high-grade premalignant airway lesions and becomes elevated in peripheral blood, thereby defining rapid progression during early-stage non-small cell lung cancer development. | Alright, I need to summarize the main finding of this biomedical study in exactly one sentence. Let me break down what I'm reading here.
The study is about lung cancer, specifically non-small cell lung cancer (NSCLC), and it's focusing on early detection and intervention. The key question is about the relationship bet... | Title: A preinvasive regulatory T cell axis for lung cancer interception. | Abstract: Late-stage non-small cell lung cancer (NSCLC) is rarely curable1, underscoring a need to intervene earlier in the disease process. Growing evidence suggests that antitumour T cell responses are mounted but become progressively dysregu... | Title: A preinvasive regulatory T cell axis for lung cancer interception. | Abstract: Late-stage non-small cell lung cancer (NSCLC) is rarely curable1, underscoring a need to intervene earlier in the disease process. Growing evidence suggests that antitumour T cell responses are mounted but become progressively dysregu... | # Constraints
The question you must answer is from a science domain. You are a senior translational oncologist and immunologist with 20 years of experience specializing in early-stage lung cancer detection. Based in a leading research hospital, you expertly interpret multi-omic profiling data to bridge laboratory findi... |
Summarize the main finding of this biomedical study in one sentence. | Immune-mediated myositis can be a severe side effect of cancer treatment involving immune checkpoint inhibitors (ICI). | ### Task
Summarize the main finding of the provided biomedical study abstract in exactly one sentence.
### Input Data
**Title:** [Myositis induced by immune checkpoint inhibitor therapy]
**Abstract:** Immune-mediated myositis can be a severe side effect of cancer treatment involving immune checkpoint inhibitors (ICI)... | Immune checkpoint inhibitor-induced myositis is a severe, early-onset adverse event that requires immediate high-dose glucocorticoid therapy upon suspicion, with overlap syndromes involving myocarditis or myasthenia gravis conferring significantly higher rates of mechanical ventilation and a 40% mortality rate. | Alright, I need to summarize this abstract in exactly one sentence. Let me break down what's important here.
The abstract is about myositis caused by immune checkpoint inhibitors (ICI). Key points I'm picking up: it's a severe side effect, happens usually within 1 month of starting ICI therapy, incidence is 0.5-1% but... | Title: [Myositis induced by immune checkpoint inhibitor therapy]. | Abstract: Immune-mediated myositis can be a severe side effect of cancer treatment involving immune checkpoint inhibitors (ICI). As a distinct type of rheumatic immune-related adverse events (irAE), it presents challenges in terms of diagnosis and pati... | Title: [Myositis induced by immune checkpoint inhibitor therapy]. | Abstract: Immune-mediated myositis can be a severe side effect of cancer treatment involving immune checkpoint inhibitors (ICI). As a distinct type of rheumatic immune-related adverse events (irAE), it presents challenges in terms of diagnosis and pati... | # Constraints
The question you must answer is from a medical domain. You are a senior oncologist and rheumatologist specializing in immune-related adverse events from cancer therapies. With 20 years of clinical experience and active involvement in global pharmacovigilance registries, you possess unparalleled expertise ... |
List the MeSH terms that index this study. | Humans | mRNA Vaccines | Bioengineering | Animals | RNA, Messenger | Immunity, Innate | Extract and list the Medical Subject Headings (MeSH) terms that best index the study described below. MeSH terms are a controlled vocabulary thesaurus used for indexing articles in the life sciences.
### Study Content
**Title:** Bioengineering strategies for improving the immunogenicity of mRNA vaccines.
**Abstract:**... | Based on the provided title and abstract, the following MeSH terms best index this study:
* **RNA, Messenger**
* **mRNA Vaccines**
* **Immunogenicity, Vaccine**
* **Biomedical Engineering**
* **Genetic Engineering**
* **Drug Delivery Systems**
* **Immunity, Innate**
* **Immunity, Cellular**
* **Immun... | Okay, let me look at this prompt. I need to extract MeSH terms that best index a study about mRNA vaccine bioengineering and immunogenicity.
Let me break down the title and abstract carefully. The title mentions "Bioengineering strategies for improving the immunogenicity of mRNA vaccines." So right away, I'm seeing se... | Title: Bioengineering strategies for improving the immunogenicity of mRNA vaccines. | Abstract: Messenger RNA (mRNA) vaccines have reshaped modern vaccinology by enabling rapid antigen design, scalable manufacturing, and coordinated induction of humoral and cellular immunity. Their clinical success has established mRNA... | Title: Bioengineering strategies for improving the immunogenicity of mRNA vaccines. | Abstract: Messenger RNA (mRNA) vaccines have reshaped modern vaccinology by enabling rapid antigen design, scalable manufacturing, and coordinated induction of humoral and cellular immunity. Their clinical success has established mRNA... | # Constraints
The question you must answer is from a science domain. You are a senior biomedical librarian and immunology researcher specializing in mRNA vaccine bioengineering. With a PhD in Molecular Biology and 15 years of experience indexing clinical trials for the National Library of Medicine, you possess encyclop... |
Summarize the main finding of this biomedical study in one sentence. | Lung cancer imposes the highest cancer-related mortality burden worldwide, while its responsiveness to immunotherapy is often constrained by the immunosuppressive pulmonary tumor microenvironment (TME) and tumor adaptations that buffer oxidative stress. | ### Task
Summarize the main finding of the provided biomedical study abstract into a single, concise sentence.
### Constraints
- **Length**: Exactly one sentence.
- **Focus**: Highlight the primary mechanism and outcome.
- **Content**: Use only the information provided in the text below.
### Input Text
**Title**: Inh... | An inhalable fluorinated polymer nanoplatform (PFAP) triggers mitochondrial dysfunction to induce GSDME-mediated pyroptosis within the acidic tumor microenvironment, thereby eliciting robust antitumor immunity and suppressing lung tumor progression without detectable systemic toxicity. | Okay, let me parse this prompt carefully. I need to summarize a biomedical study abstract into exactly one sentence, focusing on the primary mechanism and outcome, using only the information in the text.
Let me read through the abstract to identify the key elements.
The title tells me it's about an "Inhaled Fluorinat... | Title: Inhaled Fluorinated Polymer Triggers Pyroptosis for Lung Cancer Immunotherapy. | Abstract: Lung cancer imposes the highest cancer-related mortality burden worldwide, while its responsiveness to immunotherapy is often constrained by the immunosuppressive pulmonary tumor microenvironment (TME) and tumor adaptation... | Title: Inhaled Fluorinated Polymer Triggers Pyroptosis for Lung Cancer Immunotherapy. | Abstract: Lung cancer imposes the highest cancer-related mortality burden worldwide, while its responsiveness to immunotherapy is often constrained by the immunosuppressive pulmonary tumor microenvironment (TME) and tumor adaptation... | # Constraints
The question you must answer is from a science domain. You are a senior biomedical researcher and oncology specialist in your late 40s, based at a leading cancer research institute. You possess deep expertise in nanomedicine, tumor microenvironments, and immunotherapy mechanisms. Your career focuses on tr... |
End of preview. Expand in Data Studio
Diversa-Med-Instruct (v0.1, proof)
Biomedical instruction data grounded in real sources.
- Grounding: each row's
completionis copied verbatim from a real PubMed abstract (first sentence) or a paper's real MeSH terms — retrieved via NCBI E-utilities. - Enhancement: Adaptation Labs (
adapt: deduplication, prompt rephrasing, reasoning traces) produced theenhanced_promptfield. Only the prompt wording is machine-generated; answers are never synthetic. - Columns:
prompt,completion,enhanced_prompt(+ context folded into the prompt by the platform).
Not a substitute for the source literature; a derived instruction artifact. Base content: PubMed abstracts (NLM) and MeSH (public domain).
- Downloads last month
- -